Philis-Tsimikas, Athena http://orcid.org/0000-0002-3986-9630
,
Klonoff, David C.
Khunti, Kamlesh
Bajaj, Harpreet S.
Leiter, Lawrence A.
Hansen, Melissa V.
Troelsen, Lone N.
Ladelund, Steen
Heller, Simon
Pieber, Thomas R.
Funding for this research was provided by:
Novo Nordisk
Article History
Received: 9 September 2019
Accepted: 4 December 2019
First Online: 27 January 2020
Duality of interest
: APT has served on advisory panels for Eli Lilly and Co., Dexcom, Inc. and Voluntis, provided consultancy services for Novo Nordisk A/S and Sanofi US, and received research support from Merck & Co., Inc., Novo Nordisk A/S, Sanofi US, Eli Lilly and Co., AstraZeneca, Janssen Pharmaceuticals, Inc. and Genentech, Inc. APT does not receive any direct or indirect payment for these services. DCK is a consultant for Abbott, Ascensia, EOFlow, Know, Lifecare, Merck, Novo Nordisk, Roche and Voluntis. KK has received honoraria from AstraZeneca, Boehringer Ingelheim, Eli Lilly, Janssen, Merck Sharp & Dohme, Novartis, Novo Nordisk, Roche and Sanofi, and research support from AstraZeneca, Boehringer Ingelheim, Eli Lilly, Janssen, Merck Sharp & Dohme, Novartis, Novo Nordisk, Roche and Sanofi, and also acknowledges support from the National Institute for Health Research Collaboration for Leadership in Applied Health Research and Care – East Midlands (NIHR CLAHRC – EM) and the National Institute of Health Research (NIHR) Leicester Biomedical Research Centre. HSB reports speaking honoraria or research support from Abbott, Amgen, AstraZeneca, Boehringer Ingelheim, Eli Lilly, Janssen, Merck, Novo Nordisk and Sanofi. LAL has received research support from AstraZeneca, Boehringer Ingelheim, Eli Lilly, GSK, Janssen, Novo Nordisk and Sanofi, and has been on advisory panels and provided continuing medical education for AstraZeneca, Boehringer Ingelheim, Eli Lilly, Janssen, Merck, Novo Nordisk, Sanofi and Servier. MVH, LNT and SL are full-time employees of, and hold stock in, Novo Nordisk A/S. SH has served on speaker panels for Eli Lilly and Novo Nordisk, for which he has received remuneration. He has served on advisory panels or as a consultant for Zeeland, UNEEG Medical, Boehringer Ingelheim, Novo Nordisk, Eli Lilly, Sanofi Aventis and Takeda, for which his institution has received remuneration. TRP has received research support from Novo Nordisk and AstraZeneca (paid directly to the Medical University of Graz) and personal fees as a consultant from Adocia, Arecor, AstraZeneca, Eli Lilly, Novo Nordisk and Sanofi. TRP is also the Chief Scientific Officer of CBmed (Center for Biomarker Research in Medicine), a public-funded biomarker research company.